



# TEXAS MEDICAID Clinical Edit Prior Authorization alirocumab (PRALUENT)

## STEP 1: CLEARLY PRINT AND COMPLETE TO EXPEDITE PROCESSING

Date:	Prescriber First & Last Name:
Patient First & Last Name:	Prescriber NPI:
Patient Address:	Prescriber Address:
Patient ID:	Prescriber Phone:
Patient Date of Birth:	Prescriber Fax:

## STEP 2: MEDICATION INFORMATION

Medication Requested (Name):	Quantity Requested:
Dose Requested:	Dosing Instructions:

Patient's Primary Diagnosis: \_\_\_\_\_ ICD 10 Code: \_\_\_\_\_

Indicate the drug's formulary status: \*(Formulary available at [www.txvendordrug.com](http://www.txvendordrug.com))

- Non-Preferred Drug (NPD or NAP Status, Go to Step 3 - PDL PA Criteria Applies)  
**OR**  Preferred Drug (Go to Step 4)  
**OR**  No Status, Drug is not in a Market Basket (Go to Step 4)  
**OR**  N/A as this request is for a CHIP / PERINATE client (Go to Step 4)

## STEP 3: PDL PRIOR AUTHORIZATION CRITERIA FOR NON-PREFERRED PRODUCT

1. Has the client failed a 30-day treatment trial with atorvastatin, rosuvastatin and ezetimibe in the last 180 days?

- Yes (Go to #2)  No (Go to #3)

2. Will the client have concurrent therapy with atorvastatin or rosuvastatin?

- Yes (Go to Step 4, Question 1)  No (Go to #3)



# TEXAS MEDICAID Clinical Edit Prior Authorization alirocumab (PRALUENT)

3. Is there a documented allergy or contraindication to preferred agents in this class?

Yes (Go to Step 4, Question 1)  No (Go to #4)

4. Is the drug necessary for treatment of stage-4 advanced metastatic cancer and associated conditions?

Yes (Go to Step 4, Question 1)  No (Deny)

## STEP 4: CLINICAL PRIOR AUTHORIZATION CRITERIA

1. Has the provider submitted a Prior Authorization (PA) form for the request?

Yes (Go to #2)  No (Deny)

2. Is the client greater than or equal to ( $\geq$ ) 18 years of age?

Yes (Go to #3)  No (Deny)

3. Does the client have a diagnosis of primary hyperlipidemia or homozygous familial hypercholesterolemia (HoFH) in the last 730 days?

Yes (Go to #5)  No (Go to #4)

4. Does the client have a diagnosis of clinical atherosclerotic cardiovascular disease (ASCVD) in the last 730 days?

Yes (Go to #5)  No (Deny)

5. Does the client have a concurrent claim for atorvastatin (LIPITOR) or rosuvastatin (CRESTOR)?

Yes (Go to #6)  No (Deny)

6. Does the client have 1 claim for alirocumab (PRALUENT) or evolocumab (REPATHA) in the last 90 days?

Yes (Go to #7)  No (Go to #8)

7. Has the client shown clinical response (significant lowering of low-density lipoprotein cholesterol (LDL-C)\*) since initiation of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor therapy? [Manual Step]

Yes (Approve – 180 days)  No (Deny)

\*Significant lowering of LDL-C is defined as a 30% decrease in LDL for patients with a diagnosis of homozygous familial hypercholesterolemia and a 50% decrease in LDL for patients with a diagnosis of primary hyperlipidemia and/or clinical ASCVD



# TEXAS MEDICAID Clinical Edit Prior Authorization alirocumab (PRALUENT)

8. Does the client have at least 90 consecutive days of high dose atorvastatin therapy, 90 consecutive days of high dose rosuvastatin therapy, and 90 consecutive days of ezetimibe (ZETIA) therapy in the last 730 days?

Examples of high dose statin therapy include 40mg to 80mg doses of atorvastatin (LIPITOR) and 20mg to 40mg of rosuvastatin (CRESTOR, EZALLOR SPRINKLE).

Yes (Go to #9)

No (Deny)

9. Does the client have a documented low-density lipoprotein cholesterol (LDL-C) of greater than (>) 70mg/dL? [Manual Step]

Yes (Approve – 180 days)

No (Deny)

**STEP 5: SIGN AND FAX TO: NAVITUS PRIOR AUTHORIZATION AT: 855-668-8553**

**Prescriber Signature:** \_\_\_\_\_ **Date:** \_\_\_\_\_

If criteria not met, submit chart documentation with form citing complex medical circumstances.  
For questions, please call Navitus Customer Care at 1-877-908-6023.